Genmab A/S (GNMSF) EPS Estimated At $1.76

March 18, 2018 - By Marie Mckinney

 Genmab A/S (GNMSF) EPS Estimated At $1.76

Analysts expect Genmab A/S (OTCMKTS:GNMSF) to report $1.76 EPS on March, 27.GNMSF’s profit would be $109.46M giving it 29.90 P/E if the $1.76 EPS is correct. The stock increased 0.24% or $0.51 during the last trading session, reaching $210.51. About 259 shares traded. Genmab A/S (OTCMKTS:GNMSF) has 0.00% since March 18, 2017 and is . It has underperformed by 16.70% the S&P500.

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company has market cap of $13.09 billion. The firm markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma ; and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). It has a 71.31 P/E ratio. The Company’s products under development include Ofatumumab to treat CLL, follicular lymphoma, and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, amyloidosis, and solid tumors; Tisotumab vedotin, HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies.

More notable recent Genmab A/S (OTCMKTS:GNMSF) news were published by: Globenewswire.com which released: “Genmab 2017 Annual Report” on February 21, 2018, also Marketwatch.com with their article: “Genmab A/S” published on October 19, 2017, Bloomberg.com published: “After Soaring 3000% in 5 Years, Genmab Tests Stock-Market Habit” on December 18, 2017. More interesting news about Genmab A/S (OTCMKTS:GNMSF) were released by: Reuters.com and their article: “Genmab and Johnson & Johnson ‘love’ partnership as some ponder takeover” published on November 30, 2017 as well as Seekingalpha.com‘s news article titled: “Genmab Looks Attractive As Company Raises Its Full-Year Outlook” with publication date: December 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: